07:00 , May 24, 2010 |  BioCentury  |  Finance

Normalizing oxygen

Investors are hoping to get the lead candidate for NormOxys Inc. through Phase IIa trials in two indications with $17.5 million from a series B1 round, Jerry Karabelas of Care Capital told Ebb & Flow. The...
08:00 , Jan 25, 2010 |  BioCentury  |  Finance

SVLS closes V fund

While the pace of venture fundraising suggests some VCs are having trouble raising new funds, SV Life Sciences has closed its fifth fund on target at $400 million, with the prospects of surpassing $500 million. "2009...
08:00 , Dec 21, 2009 |  BioCentury  |  Product Development

Valuing Array's Sensitive Side

Array BioPharma Inc.'s glucokinase activators are not the most advanced molecules in the class, but the biotech says they may have a competitive advantage in terms of safety due to their glucose sensitivity. Amgen Inc....
08:00 , Nov 10, 2008 |  BioCentury  |  Finance

Biotech exits

Biotech exits Company First invested Focus Exit details Alantos 2003 - early stage Drugs targeted at osteoarthritis and inflammatory processes Acquired by Amgen (NASDAQ:AMGN) for $300M in cash...
07:00 , Aug 18, 2008 |  BioCentury  |  Finance

Ebb & Flow

Investors reached new heights of optimism after a special committee of three independent Genentech board members rejected Roche’s offer to buy the 44.1% of the biotech it doesn’t own for $89 a share, or $43.7...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders, Biogen Idec (BIIB) said it had not received any definitive offers and would remain independent. The announcement came after market close on Wednesday and BIIB plunged $17.97 (24%) to $57.91...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing power...
07:00 , Aug 27, 2007 |  BioCentury  |  Strategy

Targeting DPP-4

Targeting DPP-4 Company Product Status Novartis Galvus vildagliptin (LAF237) FDA approvable letter (resubmit NDA mid-09) AstraZeneca/Bristol-Myers/Otsuka Saxagliptin Ph III (submit NDA 1H08) Takeda Alogliptin (SYR322) [from Syrrx acq] Ph III Phenomix PHX1149 Ph IIb Glenmark/...
07:00 , Jul 23, 2007 |  BC Week In Review  |  Company News

Alantos, Amgen deal

AMGN completed its previously announced acquisition of Alantos for $300 million in cash (see BioCentury, June 11). Alantos Pharmaceuticals Holding Inc., Cambridge, Mass.   Amgen Inc. (AMGN), Thousand Oaks, Calif.   Business: Endocrine, Autoimmune   ...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

Amgen, Alantos, Ilypsa deal

AMGN will acquire Alantos and Ilypsa. AMGN will acquire Alantos for $300 million in cash. Alantos' lead compound is ALS 2-0426, which is in Phase IIa testing to treat Type II diabetes. Servier (Neuilly-sur-Seine,...